Details of Disease

General Information of Disease (ID: DIS985MG)

• Disease Name: Gliosarcoma
• Synonyms: sarcomatous glioblastoma; glioblastoma with sarcomatous component; gliosarcoma; glioblastoma with a sarcomatous component
• Definition: A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).
• Disease Hierarchy:
  DISESTHB: Glioblastoma of brain
  DIS985MG: Gliosarcoma
• Disease Identifiers:
  MONDO ID: MONDO_0016681
  MESH ID: D018316
  UMLS CUI: C0206726
  MedGen ID: 64638
  Orphanet ID: 251576
  SNOMED CT ID: 35262004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Dacarbazine	DMNPZL4	Approved	Small molecular drug	[1]
Temozolomide	DMKECZD	Approved	Small molecular drug	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 10 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
CYP2B6	TTMH124	moderate	Therapeutic	[3]
FGFR1	TTRLW2X	moderate	FusionGene	[4]
FGFR3	TTST7KB	moderate	FusionGene	[4]
NFKBIA	TTSHAEB	moderate	Biomarker	[5]
PPARG	TTT2SVW	moderate	Biomarker	[6]
PTGS1	TT8NGED	moderate	Biomarker	[7]
TACC3	TTQ4UFD	moderate	FusionGene	[4]
IDH1	TTV2A1R	Strong	Genetic Variation	[8]
MGMT	TTJ8DV7	Strong	Posttranslational Modification	[9]
POR	TTOQ9GZ	Strong	Therapeutic	[10]

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP2C18	DEZMWRE	Strong	Therapeutic	[10]

This Disease Is Related to 8 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
LZTR1	OTIDM6XO	moderate	SomaticCausalMutation	[11]
SEPTIN14	OTCM6DDO	moderate	FusionGene	[12]
TACC1	OTGX20TE	moderate	FusionGene	[4]
FREM2	OTEK6BZR	Strong	Biomarker	[13]
H3-3B	OT9XHQ3C	Strong	Genetic Variation	[14]
LHFPL6	OTY6LHJY	Strong	Biomarker	[13]
STOML3	OTLQGALK	Strong	Biomarker	[13]
TTC4	OTAPMYXU	Strong	Biomarker	[15]

References

• [1] Dacarbazine FDA Label
• [2] Temozolomide FDA Label
• [3] Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.Cancer Res. 2001 Jun 1;61(11):4437-44.
• [4] Transforming fusions of FGFR and TACC genes in human glioblastoma.Science. 2012 Sep 7;337(6099):1231-5. doi: 10.1126/science.1220834. Epub 2012 Jul 26.
• [5] Identification of a NFKBIA polymorphism associated with lower NFKBIA protein levels and poor survival outcomes in patients with glioblastoma multiforme.Int J Mol Med. 2014 Nov;34(5):1233-40. doi: 10.3892/ijmm.2014.1932. Epub 2014 Sep 12.
• [6] Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population.J Med Genet. 2000 Jun;37(6):410-4. doi: 10.1136/jmg.37.6.410.
• [7] Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma.J Neuroimmunol. 1999 Mar 1;95(1-2):202-8. doi: 10.1016/s0165-5728(98)00257-4.
• [8] Prognostic factors and clinical outcomes in adult primary gliosarcoma patients: a Surveillance, Epidemiology, and End Results (SEER) analysis from 2004 to 2015.Br J Neurosurg. 2020 Apr;34(2):161-167. doi: 10.1080/02688697.2019.1699903. Epub 2019 Dec 12.
• [9] Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.J Neurosurg. 2018 Apr;128(4):1133-1138. doi: 10.3171/2016.12.JNS162291. Epub 2017 Jun 16.
• [10] Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res. 1998 Oct 1;58(19):4391-401.
• [11] Genomics informs glioblastoma biology.Nat Genet. 2013 Oct;45(10):1105-7. doi: 10.1038/ng.2775.
• [12] Systematic exploration of natural and synthetic flavonoids for the inhibition of Staphylococcus aureus biofilms.Int J Mol Sci. 2013 Sep 25;14(10):19434-51. doi: 10.3390/ijms141019434.
• [13] Amplification of the STOML3, FREM2, and LHFP genes is associated with mesenchymal differentiation in gliosarcoma.Am J Pathol. 2012 May;180(5):1816-23. doi: 10.1016/j.ajpath.2012.01.027.
• [14] Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations.Clin Neuropathol. 2018 Sep/Oct;37(5):209-216. doi: 10.5414/NP301104.
• [15] A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: a comparison to 9L gliosarcoma.J Neurooncol. 1994;22(3):191-200. doi: 10.1007/BF01052919.